Seeking Alpha
28 Feb 2026, 13:25 UTC · 33w ago
Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label
Impact · against what's priced in
AMPH faces a negative outlook as FY26 revenue guidance is lowered to mid- to high-single-digit growth. The combined pressure of margin erosion from rising expenses and a lack of near-term pipeline catalysts suggests a fundamental deterioration in the growth profile.
- AMPH−0.60
No priced-in read yet
- In context
The downward revision of FY26 revenue guidance combined with margin pressure from rising R&D and SG&A costs creates a headwind for earnings. With preclinical catalysts years away, there is no immediate offset to the decline in legacy generics.
Read from the article alone
Top 1 mover · tap to explore
